Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares close up 1.81%
05/09/2025 01:47 PM - Politics
Outgoing ambassador positive on Taiwan-Vatican ties under new pope
05/09/2025 12:44 PM - Politics
Taiwan congratulates Leo XIV on being elected new pope
05/09/2025 12:29 PM - Society
KMT Keelung branch chairman detained in recall probe
05/09/2025 10:50 AM - Business
U.S. dollar up in Taipei trading
05/09/2025 10:11 AM